NASDAQ:EXEL

Exelixis Stock Insider Trading

Healthcare > Biotechnology

Buy EXEL

*Your capital is at risk

$51.60

+3.06 (+6.30%)

At Close: Jun 03, 2026

Exelixis Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -51.13. In total, the insiders bought 3.35M and sold 3.07M EXEL shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-51.13
● Buy	3.35M shares
● Sell	3.07M shares
44% Buy Activity Moderate Positive Correlation
Sell Signal High Confidence Feb 18, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -51.13. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 01, 2026 Sell	Common Stock S-Sale	Eckhardt Sue Gail Director	Director	9 812 Value: $492.0K
Jun 01, 2026 Sell	Common Stock S-Sale	Wyszomierski Jack L Director	Director	3 925 Value: $198.4K
May 27, 2026 Buy	Common Stock A-Award	Poste George Director	Director	8 367 Value: $418.6K
May 27, 2026 Buy	Common Stock A-Award	Wyszomierski Jack L Director	Director	8 367 Value: $418.6K
May 27, 2026 Buy	Common Stock A-Award	Oliver Bob Director	Director	8 367 Value: $418.6K
May 27, 2026 Buy	Common Stock A-Award	Eckhardt Sue Gail Director	Director	8 367 Value: $418.6K
May 27, 2026 Buy	Common Stock A-Award	Papadopoulos Stelios Director	Director	8 367 Value: $418.6K
May 27, 2026 Buy	Common Stock A-Award	Heyman Tomas J. Director	Director	8 367 Value: $418.6K
May 27, 2026 Buy	Common Stock A-Award	Smith Julie Director	Director	8 367 Value: $418.6K
May 27, 2026 Buy	Common Stock A-Award	Freire Maria C Director	Director	8 367 Value: $418.6K
May 27, 2026 Buy	Common Stock A-Award	Beckerle Mary C Director	Director	8 367 Value: $418.6K
May 27, 2026 Buy	Option (right to buy) A-Award	Johnson David Edward Director	Director	19 133 Value: $957.2K
May 26, 2026 Sell	Common Stock S-Sale	Aftab Dana EVP, Research And Development	Officer	43 451 Value: $2.19M
May 20, 2026 Sell	Common Stock S-Sale	Haley Patrick J. EVP, Commercial	Officer	32 110 Value: $1.60M
May 18, 2026 Sell	Common Stock S-Sale	Hefti Brenda SVP And General Counsel	Officer	6 625 Value: $332.6K
May 18, 2026 Sell	Common Stock S-Sale	Senner Christopher J. EVP And CFO	C-Suite Officer	34 901 Value: $1.75M
May 18, 2026 Buy	Common Stock G-Gift	Morrissey Michael President And CEO	CEO / President	124 047 Value: $6.18M
May 18, 2026 Sell	Common Stock G-Gift	Morrissey Michael President And CEO	CEO / President	124 047 Value: $0
May 15, 2026 Sell	Common Stock F-InKind	Aftab Dana EVP, Research And Development	Officer	30 578 Value: $1.56M
May 15, 2026 Sell	Common Stock F-InKind	Hefti Brenda SVP And General Counsel	Officer	6 411 Value: $327.6K
May 15, 2026 Sell	Common Stock F-InKind	Haley Patrick J. EVP, Commercial	Officer	33 265 Value: $1.70M
May 15, 2026 Sell	Common Stock F-InKind	Senner Christopher J. EVP And CFO	C-Suite Officer	40 892 Value: $2.09M
May 15, 2026 Sell	Common Stock F-InKind	Morrissey Michael President And CEO	CEO / President	128 497 Value: $6.57M
May 07, 2026 Sell	Common Stock S-Sale	Beckerle Mary C Director	Director	7 712 Value: $373.6K
May 07, 2026 Buy	Common Stock M-Exempt	Beckerle Mary C Director	Director	3 856 Value: $89.6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT EXELIXIS

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CA...

Read Full Profile Here